Department of Psychiatry, Mayo Clinic, Rochester, MN, USA.
J ECT. 2011 Mar;27(1):51-4. doi: 10.1097/YCT.0b013e3181da84c6.
Transcranial magnetic stimulation (TMS) has recently been approved by the Food and Drug Administration for treatment of depression refractory to at least 1 antidepressant medication. Clinical psychiatrists as well as patients are likely to inquire about TMS as a therapeutic option for the depressed patient. In particular, as TMS is a procedure that has at least some superficial similarities to electroconvulsive therapy (ECT), there will be interest in using TMS as a possible alternative to ECT. On the other hand, ECT has been in use for many decades and has a well-established track record of being the most effective treatment for depression. In this article, the author reviews the efficacy, adverse effect profile, cost, and inconvenience issues for both TMS and ECT and outlines some considerations for current clinical decision making regarding the choice between these 2 modalities.
经颅磁刺激（TMS）最近已被美国食品和药物管理局批准用于治疗至少 1 种抗抑郁药物治疗无效的抑郁症。临床精神病医生和患者可能会询问 TMS 作为治疗抑郁症患者的一种选择。特别是，由于 TMS 是一种与电惊厥疗法（ECT）至少有一些表面相似的程序，因此人们有兴趣将 TMS 用作 ECT 的一种可能替代方法。另一方面，ECT 已经使用了几十年，并且在治疗抑郁症方面有着非常有效的记录。在本文中，作者综述了 TMS 和 ECT 的疗效、不良反应谱、成本和不便问题，并概述了当前临床决策中选择这两种方法的一些考虑因素。
